Literature DB >> 18796097

Incidence and prevalence of inflammatory bowel disease in a Northern California managed care organization, 1996-2002.

Lisa J Herrinton1, Liyan Liu, James D Lewis, Patricia M Griffin, James Allison.   

Abstract

OBJECTIVE: There are few estimates of the incidence and prevalence of inflammatory bowel disease in North American communities. We sought to estimate the incidence and prevalence of inflammatory bowel disease (IBD), including Crohn's disease (CD), and ulcerative colitis (UC), among 3.2 million members of Kaiser Permanente, Northern California, for the period 1996-2002.
METHODS: All health plan members who had one or more diagnoses of CD (ICD-9 code 555) or UC (ICD-9 code 556) on computerized records during the period 1996-2002 and with at least 12 months of membership were identified as possible IBD cases (N = 12,059). We randomly sampled 24% of these for chart review to confirm the diagnosis and obtain the initial diagnosis date. Incidence rates and the point prevalence on December 31, 2002 were standardized to the 2000 U. S. Census.
RESULTS: The annual incidence rate per 100,000 persons was 6.3 for CD (95% confidence interval [CI], 5.6-7.0) and 12.0 for UC (CI, 11.0-13.0). The point prevalence per 100,000 on December 31, 2002 was 96.3 for CD (95% CI, 89.6-103.0) and 155.8 for UC (95% CI, 146.6-164.9), increasing to 100.3 and 205.8 per 100,000, respectively, when hospital discharge data from 1985 to 1995 were included. The age-specific incidence of CD was bimodal, while UC incidence rose in early adulthood and remained elevated with advancing age.
CONCLUSIONS: The incidence we estimated for CD was similar to the previous U. S. estimate. Our incidence estimate for UC was much higher than the previous U.S. estimate, but similar to that of recent Canadian and European studies. The prevalence we estimated for CD was somewhat lower than previous estimates.

Entities:  

Mesh:

Year:  2008        PMID: 18796097     DOI: 10.1111/j.1572-0241.2008.01960.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  59 in total

1.  Association between maternal inflammatory bowel disease and adverse perinatal outcomes.

Authors:  D Getahun; M J Fassett; G F Longstreth; C Koebnick; A M Langer-Gould; D Strickland; S J Jacobsen
Journal:  J Perinatol       Date:  2014-03-20       Impact factor: 2.521

2.  Racial and ethnic differences in health care utilization and outcomes among ulcerative colitis patients in an integrated health-care organization.

Authors:  Dan Li; Bernadette Collins; Fernando S Velayos; Liyan Liu; James D Lewis; James E Allison; Nicole T Flowers; Susan Hutfless; Oren Abramson; Lisa J Herrinton
Journal:  Dig Dis Sci       Date:  2013-10-31       Impact factor: 3.199

3.  Isotretinoin use and the risk of inflammatory bowel disease: a case-control study.

Authors:  Seth D Crockett; Carol Q Porter; Christopher F Martin; Robert S Sandler; Michael D Kappelman
Journal:  Am J Gastroenterol       Date:  2010-03-30       Impact factor: 10.864

4.  Current Research in Crohn's Disease and Ulcerative Colitis: Highlights from the 2010 ACG Meeting.

Authors:  Gary R Lichtenstein
Journal:  Gastroenterol Hepatol (N Y)       Date:  2010-12

5.  Update on the Incidence and Prevalence of Inflammatory Bowel Disease in the United States.

Authors:  Edward V Loftus
Journal:  Gastroenterol Hepatol (N Y)       Date:  2016-11

6.  Measures of obesity and risk of Crohn's disease and ulcerative colitis.

Authors:  Hamed Khalili; Ashwin N Ananthakrishnan; Gauree G Konijeti; Leslie M Higuchi; Charles S Fuchs; James M Richter; Andrew T Chan
Journal:  Inflamm Bowel Dis       Date:  2015-02       Impact factor: 5.325

Review 7.  Challenges in designing a national surveillance program for inflammatory bowel disease in the United States.

Authors:  Millie D Long; Susan Hutfless; Michael D Kappelman; Hamed Khalili; Gilaad G Kaplan; Charles N Bernstein; Jean Frederic Colombel; Corinne Gower-Rousseau; Lisa Herrinton; Fernando Velayos; Edward V Loftus; Geoffrey C Nguyen; Ashwin N Ananthakrishnan; Amnon Sonnenberg; Andrew Chan; Robert S Sandler; Ashish Atreja; Samir A Shah; Kenneth J Rothman; Neal S Leleiko; Renee Bright; Paolo Boffetta; Kelly D Myers; Bruce E Sands
Journal:  Inflamm Bowel Dis       Date:  2014-02       Impact factor: 5.325

8.  Development and validation of a registry-based definition of eosinophilic esophagitis in Denmark.

Authors:  Evan S Dellon; Rune Erichsen; Lars Pedersen; Nicholas J Shaheen; John A Baron; Henrik T Sørensen; Mogens Vyberg
Journal:  World J Gastroenterol       Date:  2013-01-28       Impact factor: 5.742

9.  Hormone therapy increases risk of ulcerative colitis but not Crohn's disease.

Authors:  Hamed Khalili; Leslie M Higuchi; Ashwin N Ananthakrishnan; JoAnn E Manson; Diane Feskanich; James M Richter; Charles S Fuchs; Andrew T Chan
Journal:  Gastroenterology       Date:  2012-07-27       Impact factor: 22.682

10.  Mycobacterium avium subspecies paratuberculosis, Crohn's disease and the Doomsday scenario.

Authors:  John Hermon-Taylor
Journal:  Gut Pathog       Date:  2009-07-14       Impact factor: 4.181

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.